You are here:

Forthcoming Submission: brodalumab (Kyntheum)

Indication: For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.

Drug Details

Drug Name: brodalumab (Kyntheum)
Drug Manufacturer: LEO Pharmaceuticals
BNF Category:
Submission type: Resubmission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: 3/04/2018
Advice Due: 7/05/2018